knowledge -WSS

knowledge

author：fashion 2025-10-03 01:05:39 - browse：78884

Adobe

The federal government inappropriately lowered the 2024 Medicare Advantage star ratings of SCAN Health Plan, which led to the health insurance company in California losing hundreds of millions of dollars in bonuses from the government, a judge ruled Monday.

The decision will lead to more than $250 million funneling back into SCAN, which covers 270,000 Medicare Advantage enrollees. And it opens the door for other Medicare Advantage plans to potentially recoup huge sums of taxpayer-funded bonuses — even though many independent experts believe the quality rating system is flawed and doesn’t appropriately gauge quality of care for older adults and people with disabilities.

The Centers for Medicare and Medicaid Services, the federal agency that oversees all Medicare programs, said it does not comment on litigation. In an interview, SCAN CEO Sachin Jain told STAT that if the company had not gotten its expected bonus money, it would have had to shave benefits and reduce what it pays hospitals and doctors.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily market-moving biopharma analysis — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： Americans' trust in science, scientist continues decline: Report

WSS

Patients' immediate access to test results puts radiologists in a bind

Trump attorney outlines possible Jan. 6 legal defenses, but some experts are skeptical

What causes an itch? Researchers may have solved the mystery

Ohioans vote in high

FDA approves world's first CRISPR

Pharma patents targeted by Biden in move to slash drug prices

Wikipedia

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily market-moving biopharma analysis — by subscribing to STAT+.

focus

FDA approval of Sarepta Duchenne genetic therapy gives me hope

FDA needs staff influx to meet gene therapy needs, Marks says

Guidelines to prevent youth baseball injuries need more muscle

Astronauts get first look at the spacecraft that will fly them around the moon

Novavax promises a turnaround & Lilly roils the obesity market

Sage's campaign to raise awareness of postpartum depression hits a nerve

How one medical school became remarkably diverse

Biden praises World Series champion Astros for impact off the field during White House celebration

Psychedelics group wrestles with new pharma identity

CMS should re

leisure time

AbbVie buys Immunogen, maker of targeted cancer drugs, for $10B

Americans' trust in science, scientist continues decline: Report

Trump attorney outlines possible Jan. 6 legal defenses, but some experts are skeptical

CMS should re

More regulation could be coming for drug ads

'Of course' Trump lost the 2020 election, DeSantis says after years of hedging

knowledge

hotspot

knowledge

hotspot